9 hrs ago | The South Mississippi Sun Herald
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Rigel Pharmaceuticals, Inc. today announced that R788 produced significant clinical improvement in rheumatoid arthritis patients in the recently completed TASKi2 Phase 2b clinical trial of 457 patients treated for up to 6 months.
Arthritis Drug Raises Risk of Tuberculosis
An arthritis therapy appears to increase the risk of tuberculosis in certain patients, French researchers have found.
Array BioPharma Announces Top-Line Results In Two Phase 1 Clinical Trials
Array BioPharma Inc. announced top-line results from its Phase 1 seven-day dose escalation trial up to 1,200 mg daily of p38 inhibitor, ARRY-797, in healthy volunteers.
Scientists Lay Out Gene Map Of Korean Male
Scientists have sequenced the entire gene map of a Korean male and linked DNA variations unique to him to possible susceptibility to various cancers and other diseases like rheumatoid arthritis.
The South Mississippi Sun Herald
Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive...
ACCESS PHARMACEUTICALS, INC. announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis .
Presse Release: Further interim analyses confirm good clinical...
Presse Release: Further interim analyses confirm good clinical efficacy of the BT-061 monoclonal antibody.
Autism May Be Linked to Mom's Autoimmune Disease
Children of mothers who have autoimmune diseases such as type 1 diabetes, rheumatoid arthritis and celiac disease have up to a three times greater risk for autism, a new study finds.
The immunopathogenesis of rheumatoid arthritis.
NEW benj ra NEW Abstract Rheumatoid arthritis is a chronic inflammatory polyarthritis whose etiology remains uncertain.
Column: Explore options for arthritis in shoulder
If you have shoulder pain that affects your daily activities and recreation and is getting progressively worse, you may have developed arthritis.
Rheumatoid Arthritis: New Treatment Target
June 30, 2009 -- Scientists have found a potential new target for rheumatoid arthritis treatment .
Nearly Half Of Rheumatoid Arthritis Sufferers Feel Early Treatment...
A UK survey of 575 rheumatoid arthritis sufferers highlights the importance of maintaining independence and the significant impact that early diagnosis and treatment can have.
What's the difference between rheumatoid and osteoarthritis? When you think of arthritis, you probably picture joints that start aching as you get older and worsen thanks to excess weight or lack of physical activity .
Abbott Labs suit could lessen blow of $1.7 billion verdict
Though Abbott Laboratories lost a nearly $1.7 billion patent verdict for a blockbuster drug, analysts expect Abbott to negotiate an agreement with court victor Johnson & Johnson that would allow both companies to derive benefits from each other's drugs.
Arthritis literally means "Inflammation of Joint", there are various types of arthritis, most common are Osteoarthritis and Rheumatoid Arthritis.
Risk of tuberculosis from arthritis medication examined
Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis.
Jury finds Abbott infringed on J&J's patent; Abbott plans to appeal $1.67B ruling
Abbott Laboratories plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders.
New Rheumatoid Arthritis Drug in the Works
June 29, 2009 -- An experimental drug called masitinib may ease rheumatoid arthritis symptoms in people who aren't helped by other drugs, a new study shows.
New Drug Promising Against Rheumatoid Arthritis
The immunosuppressive drug golimumab shows promise in treating rheumatoid arthritis patients who don't respond to other drugs, according to a new study.
Golimumab shows promise for rheumatoid arthritis
Golimumab, a new tumour necrosis factor-I inhibitor reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-I inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF-I inhibitors, finds an Article published Online first and in this week's edition ...
New trigger for chronic inflammation in rheumatoid arthritis discovered
A signal molecule made by the human body that triggers the immune system into action may be important in rheumatoid arthritis, according to new research published today in Nature Medicine .